Navigation Links
Genta Receives Key Patent Related to Oral Gallium Compound G4544
Date:4/14/2008

roval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today announced ... Wall to the Company,s Board. Mr. ... Boston -based investment firm, for more than ... Board of Directors, and chair of the Corporate Governance Committee ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Acquire Exclusive Rights to Gastrin Based Therapies Program for ... ... TORONTO, March 13 Eli Lilly,and Company (NYSE: LLY ) ... two companies have entered into a licensing,and collaboration agreement granting Lilly ...
... KANSAS CITY, Mo., March 13 Synbiotics Corporation ... the Food & Drug,Administration (FDA) for the use ... in humans. This represents Synbiotics first foray into ... Synbiotics,initial intent to market this product itself to ...
Cached Medicine Technology:Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 2Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 3Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 4Synbiotics Corporation Announces Human Submission for FluDetect(R) 2
(Date:9/2/2015)... Boston, MA (PRWEB) , ... September 02, 2015 ... ... reports covering healthcare innovation and investment, announced the two leaders who will deliver ... Boston on November 3, at the Mandarin Oriental Hotel in Boston. , Larry ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and ... mixed documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps ... to reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... obesity being so much in the center of attention now ... cute, chubby babies might actually be too fat //for their ... crafted message that are coming from several top health groups, ... Control and Prevention and the American Academy of Pediatrics as ...
... to an outbreak of mosquito-borne encephalitis B in China, the ... to the 26 people already killed by the disease. ... infected with the disease and 40 of them have died ... in the first six months of 2006. But the newspaper ...
... a study published in the August issue of the Journal, ... have found //that certain risks factors put people younger than ... The findings were based on the study done on ... of people over 60. ,Peripheral vascular disease ...
... disclosed that a specific variety of adult ... neurons or other// types of tissue depending on the ... ,The researchers found that mesenchymal stem cells, which are ... clues from their local environment, allowing a transformation into ...
... exempting mental health units from the ban on smoking ... in the health of people// suffering mental ailments. Smoking ... premature death in the United Kingdom, with nearly 106,000 ... , ,The Health Act 2006 will make ...
... small study revealed that botox injections can help in healing ... Sherris, professor and chair of the department of otolaryngology at ... He said ” This is the first medication found to ... of Mayo Clinic Proceedings. ,The study was conducted ...
Cached Medicine News:Health News:Chubbiness In Babies Might Not Be A Cute Sign 2Health News:Adult stem cells are sensitive to responses from the environment 2Health News:Smoking Ban should Include Mental Health Units 2
Inquire...
... K2 / gel tubes are for ... molecular diagnostics and for viral load ... blood remain stable at room temperature ... optimal results, it is recommended to ...
Glass Whole Blood Tube with K3EDTA...
... transglutaminase (tTg) is a ubiquitous enzyme ... Tissue transglutaminase is also the specific ... endomysial antibody immunofluorescence (EMA) tests (Bio-Rad ... IgA and,IgG serologic tests are highly ...
Medicine Products: